Charles River Laboratories International, Inc. (CRL) Yield on Cost (YOC): N/A
The yield on cost (YOC) for Charles River Laboratories International, Inc. (CRL) is N/A.
CRL Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Charles River Laboratories International, Inc. (CRL) based on your custom cost basis.
Starting Yield
1.06%
Ending YOC
3.37%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 1.06% | $0.00 |
| Year 1 | $2.16 | +8.00% | 1.15% | $2.16 |
| Year 2 | $2.33 | +8.00% | 1.24% | $4.49 |
| Year 3 | $2.52 | +8.00% | 1.34% | $7.01 |
| Year 4 | $2.72 | +8.00% | 1.45% | $9.73 |
| Year 5 | $2.94 | +8.00% | 1.56% | $12.67 |
| Year 6 | $3.17 | +8.00% | 1.69% | $15.85 |
| Year 7 | $3.43 | +8.00% | 1.82% | $19.27 |
| Year 8 | $3.70 | +8.00% | 1.97% | $22.98 |
| Year 9 | $4.00 | +8.00% | 2.13% | $26.97 |
| Year 10 | $4.32 | +8.00% | 2.30% | $31.29 |
| Year 11 | $4.66 | +8.00% | 2.48% | $35.95 |
| Year 12 | $5.04 | +8.00% | 2.68% | $40.99 |
| Year 13 | $5.44 | +8.00% | 2.89% | $46.43 |
| Year 14 | $5.87 | +8.00% | 3.12% | $52.30 |
| Year 15 | $6.34 | +8.00% | 3.37% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Charles River Laboratories International, Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster